Department of Cardiovascular Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Emergency, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
J Interv Cardiol. 2022 Feb 21;2022:5488654. doi: 10.1155/2022/5488654. eCollection 2022.
Implantation of the MitraClip is a safe and effective therapy for mitral valve repair in patients ineligible for surgery or at high risk of adverse surgical outcomes. However, only limited information is available concerning sex differences in transcatheter mitral valve repair. We therefore sought to conduct a comprehensive meta-analysis of studies that investigated differences between men and women in outcomes following MitraClip implantation.
The PubMed and Embase databases were searched until November 2019 for studies reporting outcomes after MitraClip implantation in women versus men. Outcomes included all-cause mortality and major complications at 30 days and one year of follow-up.
Six studies ( = 1,109 women; = 1,743 men) were analyzed. At 30 days, women had a similar risk of postoperative complications, such as stroke, major bleeding, and pericardium effusion, without differences in all-cause mortality, procedure success, or MitraClip usage. At one year, the all-cause mortality, the reduction of mitral regurgitation, and the risk of rehospitalization for heart failure were also comparable between male and female patients.
Gender disparity was not found in complications or prognosis of patients undergoing MitraClip implantation. This study suggests that gender should not be considered as a critical factor in the selection of patients as candidates for MitraClip implantation of concern during follow-up.
对于不符合手术条件或手术不良结局风险较高的二尖瓣修复患者,植入 MitraClip 是一种安全有效的治疗方法。然而,关于经导管二尖瓣修复术后男女之间的性别差异,仅有有限的信息。因此,我们旨在对研究 MitraClip 植入术后男女患者结局差异的研究进行全面的荟萃分析。
检索 PubMed 和 Embase 数据库,直到 2019 年 11 月,以查找报告女性与男性相比接受 MitraClip 植入术后结局的研究。结局包括术后 30 天和 1 年的全因死亡率和主要并发症。
共分析了 6 项研究(女性患者 = 1109 例;男性患者 = 1743 例)。术后 30 天,女性术后并发症(如中风、大出血和心包积液)的风险相似,全因死亡率、手术成功率或 MitraClip 使用无差异。在 1 年时,全因死亡率、二尖瓣反流减少和因心力衰竭再次住院的风险在男性和女性患者之间也是相似的。
在接受 MitraClip 植入的患者中,并发症或预后方面并未发现性别差异。本研究表明,性别不应被视为 MitraClip 植入候选患者选择的关键因素,也不应在随访期间对此表示关注。